PolarityTE, Inc. (PTE) Stock Analysis
DELISTED 2023
What happened to PolarityTE, Inc. (PTE) stock?
PolarityTE, Inc. (PTE) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PolarityTE, Inc. (PTE) trades at $0.241. PolarityTE, Inc. is a clinical-stage biotechnology company focused on regenerative tissue products and biomaterials. Their lead product, SkinTE, is used for skin repair and reconstruction. Market cap: $1.78M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for PTE: PTE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PTE against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
PTE: 1/2 scored disciplines lean bullish. Dominant signal: Jim Simons bearish.
How is this calculated? →PolarityTE, Inc. (PTE) Healthcare & Pipeline Overview
PolarityTE, Inc. is a clinical-stage biotechnology company specializing in regenerative medicine, particularly skin regeneration. Its flagship product, SkinTE, addresses acute and chronic wounds, burns, and surgical reconstruction. The company operates in the competitive biotechnology sector, focusing on innovative tissue engineering solutions.
What Is the Investment Thesis for PTE?
PolarityTE, Inc. presents a high-risk, high-reward investment opportunity within the regenerative medicine sector. The company's SkinTE product addresses a significant market need in wound care and reconstructive surgery. A key value driver is the successful commercialization and clinical adoption of SkinTE and its related products, such as SkinTE Cryo and PTE 11000. The company's gross margin of 24.3% indicates potential for profitability as sales scale. Upcoming catalysts include clinical trial results for SkinTE and regulatory approvals for new product applications. However, potential risks include competition from established players, regulatory hurdles, and the need for additional financing to support ongoing operations and research and development.
Based on FMP financials and quantitative analysis
PTE Key Highlights
PolarityTE operates in the regenerative medicine sector, focusing on tissue regeneration and repair.
- The company's primary product, SkinTE, addresses a significant market need in wound care and reconstructive surgery.
- PolarityTE has a gross margin of 24.3%, indicating potential for profitability as sales scale.
- The company is developing SkinTE Cryo, which allows for multiple deployments from a single harvest through cryopreservation.
- PolarityTE's market capitalization is $0.00B as of March 17, 2026.
Who Are PTE's Competitors?
PTE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASLN ASLN | $0.60 | -14.27% | $777M | 56 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PTE's Key Strengths?
Innovative SkinTE technology with potential for broad applications.
- Proprietary technology and intellectual property.
- Focus on regenerative medicine, a growing market segment.
- Gross Profit Margin of 24.3%
What Are PTE's Weaknesses?
Clinical stage company with limited commercial revenue.
- Reliance on SkinTE as primary product.
- Need for additional financing to support ongoing operations and research and development.
- Relatively small number of employees (42).
What Could Drive PTE Stock Higher?
Clinical trial results for SkinTE in expanded indications.
- Regulatory approvals for SkinTE Cryo and PTE 11000.
- Expansion of strategic partnerships and collaborations.
What Are the Key Risks for PTE?
Financial-distress signal — its Altman Z-Score of -44.53 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established players in the wound care and regenerative medicine markets.
- Regulatory hurdles and the need for clinical trial success.
- Dependence on successful commercialization of SkinTE.
- Need for additional financing to support operations.
What Are the Growth Opportunities for PTE?
- Expansion of SkinTE Applications: PolarityTE has the opportunity to expand the applications of SkinTE beyond its current indications. This includes exploring its use in treating more complex wounds, burns, and surgical reconstruction cases. The global wound care market is projected to reach $27.2 billion by 2027, providing a substantial market for SkinTE. Successful clinical trials and regulatory approvals for these expanded applications could significantly drive revenue growth within the next 3-5 years.
- Development and Commercialization of SkinTE Cryo: The development and commercialization of SkinTE Cryo presents a significant growth opportunity. This product allows for multiple deployments from a single harvest through cryopreservation, increasing convenience and reducing costs for patients and healthcare providers. The market for cryopreserved tissues is growing, driven by advancements in cryopreservation technology and increasing demand for allografts. Launching SkinTE Cryo within the next 2 years could capture a significant share of this market.
- Advancement of PTE 11000: PTE 11000, an allogenic, biologically active dressing, represents another growth opportunity for PolarityTE. This product is intended for wound care and aesthetics to accelerate skin healing. The market for advanced wound dressings is expanding, driven by the increasing prevalence of chronic wounds and the demand for more effective healing solutions. Successful clinical trials and regulatory approval for PTE 11000 within the next 3 years could generate substantial revenue.
- Strategic Partnerships and Collaborations: PolarityTE can pursue strategic partnerships and collaborations to accelerate its growth. This includes partnering with hospitals, clinics, and other healthcare providers to increase the adoption of SkinTE and its related products. Collaborations with research institutions can also facilitate the development of new products and applications. These partnerships could be established within the next 1-2 years, leading to increased market penetration and revenue growth.
- International Expansion: PolarityTE has the opportunity to expand its operations internationally. This includes seeking regulatory approvals for SkinTE and its related products in key markets such as Europe and Asia. The global market for regenerative medicine is growing, and international expansion could significantly increase PolarityTE's revenue potential. Entering new markets within the next 3-5 years could diversify revenue streams and reduce reliance on the US market.
What Are PTE's Competitive Advantages?
- Proprietary technology and intellectual property related to SkinTE and other regenerative medicine products.
- Clinical data supporting the safety and efficacy of SkinTE.
- Established relationships with key opinion leaders and healthcare providers in the wound care and reconstructive surgery fields.
What Does PTE Do?
PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company focused on developing and commercializing regenerative tissue products and biomaterials. The company operates through two segments: Regenerative Medicine Products and Contract Services. Its primary product, SkinTE, is a tissue-based product designed for the repair, reconstruction, replacement, and supplementation of skin in patients with acute or chronic wounds, burns, surgical reconstruction needs, scar revision, or dysfunctional skin grafts. SkinTE leverages the patient's own tissue to facilitate regeneration. The company also offers contract research services. PolarityTE is further developing SkinTE Cryo, which allows for multiple deployments from a single harvest through cryopreservation, and a SkinTE point-of-care device for immediate processing and deployment. Additionally, the company is developing PTE 11000, an allogenic, biologically active dressing intended for wound care and aesthetics to accelerate skin healing. The company's focus is on advancing tissue regeneration technologies to address unmet needs in wound care and reconstructive surgery. PolarityTE aims to establish itself as a leader in regenerative medicine through continued innovation and clinical validation of its products.
What Products and Services Does PTE Offer?
- Develops and commercializes regenerative tissue products and biomaterials.
- Offers SkinTE for skin repair, reconstruction, and supplementation.
- Provides solutions for acute and chronic wounds, burns, and surgical reconstruction.
- Develops SkinTE Cryo for multiple deployments from a single harvest.
- Creates SkinTE point-of-care device for immediate processing and deployment.
- Develops PTE 11000, an allogenic, biologically active dressing for wound care and aesthetics.
How Does PTE Make Money?
- Generates revenue through the sale of SkinTE and other regenerative medicine products.
- Provides contract research services to other companies in the biotechnology and healthcare industries.
- Focuses on developing and commercializing innovative tissue regeneration technologies.
What Industry Does PTE Operate In?
The biotechnology industry is characterized by rapid innovation, intense competition, and high regulatory scrutiny. The regenerative medicine segment, in particular, is experiencing growth due to an aging population and increasing demand for advanced wound care solutions. PolarityTE operates in this dynamic landscape, competing with companies developing similar tissue-based products and therapies. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong market presence. Competitors like ASLAN Pharmaceuticals (ASLN), Fresenius Medical Care (FRES), and GMVD are also active in related healthcare markets.
Who Are PTE's Key Customers?
- Hospitals and clinics specializing in wound care and reconstructive surgery.
- Physicians and surgeons treating patients with acute and chronic wounds, burns, and other skin conditions.
- Patients requiring skin repair, reconstruction, or supplementation.
Financial Health
PolarityTE, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -44.53 places it in the distress zone, a signal of elevated financial risk.
PTE Valuation & Market Position
With a $1.78M market cap, PolarityTE, Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for PolarityTE, Inc. stands at 56.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 44.7%, showing how much profit it generates from its asset base. PTE trades at a trailing price-to-earnings ratio of 0.16, below the Healthcare sector average of ~23x. A current ratio of 6.41 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
PolarityTE, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Richard Hague. PTE has traded publicly since 1999.
PTE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative SkinTE technology with potential for broad applications.
- Proprietary technology and intellectual property.
- Focus on regenerative medicine, a growing market segment.
- Gross Profit Margin of 24.3%
Bear Case
- Clinical stage company with limited commercial revenue.
- Reliance on SkinTE as primary product.
- Need for additional financing to support ongoing operations and research and development.
- Relatively small number of employees (42).
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PTE Latest News
No recent news available for PTE.
Leadership: Richard Hague
CEO
Richard Hague serves as the CEO of PolarityTE, Inc. His background includes experience in managing companies, though specific details on his prior roles and education are not provided in the source data. As CEO, he is responsible for leading the company's strategic direction and overseeing its operations in the regenerative medicine sector. He manages a team of 42 employees.
Track Record: Information regarding Richard Hague's specific achievements and strategic decisions at PolarityTE, Inc. is not available in the provided source data. Therefore, a detailed track record cannot be established.
PolarityTE, Inc. Healthcare Stock: Key Questions Answered
What happened to PolarityTE, Inc. (PTE) stock?
PolarityTE, Inc. (PTE) no longer trades on public markets. It was delisted in June 2023. The figures below are historical and are not a current quote.
Can I still buy PTE shares?
No. PTE stopped trading on public markets in June 2023, so the shares are not available through a broker. Anything you see quoted for PTE elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PTE stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to PolarityTE, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does PolarityTE, Inc. do?
PolarityTE, Inc. is a clinical-stage biotechnology company focused on developing and commercializing regenerative tissue products and biomaterials. Their primary product, SkinTE, is designed for the repair, reconstruction, replacement, and supplementation of skin in patients with acute or chronic wounds, burns, surgical reconstruction needs, scar revision, or dysfunctional skin grafts.
What are the main risks for PTE?
PolarityTE, Inc. faces several risks common to clinical-stage biotechnology companies. These include the need for successful clinical trial outcomes and regulatory approvals for its products, particularly SkinTE. Competition from established players in the wound care and regenerative medicine markets poses a significant challenge. The company's reliance on SkinTE as its primary product creates concentration risk.
How does PolarityTE, Inc. manage regulatory risks associated with its regenerative medicine products?
PolarityTE, Inc. navigates regulatory risks by adhering to stringent guidelines set by the FDA and other regulatory bodies. This involves conducting thorough preclinical and clinical trials to demonstrate the safety and efficacy of its products, particularly SkinTE. The company also invests in quality control and manufacturing processes to ensure compliance with regulatory standards.
What is PolarityTE, Inc.'s strategy for protecting its intellectual property related to SkinTE and other regenerative medicine technologies?
PolarityTE, Inc. employs a multi-faceted strategy to protect its intellectual property. This includes filing patents for its innovative technologies, such as SkinTE and SkinTE Cryo, to secure exclusive rights to its inventions. The company also utilizes trade secrets to protect confidential information and know-how.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited source data. AI analysis is pending, which could provide further insights.